| Literature DB >> 34313863 |
Katsuyoshi Matsuoka1, Hirono Ishikawa2, Takeo Nakayama3, Yusuke Honzawa4, Atsuo Maemoto5, Fumihito Hirai6, Fumiaki Ueno7, Noriko Sato8, Yutaka Susuta8, Toshifumi Hibi9.
Abstract
BACKGROUND: The relationship of bidirectional sharing of information between physicians and patients to patient satisfaction with treatment decision-making for ulcerative colitis (UC) has not been examined. Here, we conducted a web-based survey to evaluate this relationship.Entities:
Keywords: Patient satisfaction; Physician–patient communication; Ulcerative colitis
Mesh:
Year: 2021 PMID: 34313863 PMCID: PMC8370900 DOI: 10.1007/s00535-021-01811-1
Source DB: PubMed Journal: J Gastroenterol ISSN: 0944-1174 Impact factor: 7.527
Patient demographic and clinical characteristics
| Sex | ||
| Male, | 172 (37.6) | |
| Female, | 285 (62.4) | |
| Age, years (mean ± SD) | 43.1 ± 12.5 | |
| Time since diagnosis, years (mean ± SD) | 8.3 ± 8.5 | |
| Current symptomsa | ||
| PRO2 score (mean ± SD) | 1.4 ± 1.4 | |
| PRO2 remissionb [ | 263 (57.5) | |
| Therapeutic drug | Most recent UC relapse | Current |
| 5-ASA (enema/suppository) [ | 135 (29.5) | 117 (25.6) |
| 5-ASA (oral) [ | 253 (55.4) | 371 (81.2) |
| Corticosteroid (enema) [ | 144 (31.5) | 71 (15.5) |
| Corticosteroid (oral) [ | 167 (36.5) | 59 (12.9) |
| Corticosteroid (IV) [ | 49 (10.7) | 4 (0.9) |
| Immunomodulator (oral) [ | 73 (16.0) | 85 (18.6) |
| Immunomodulator (IV) [ | 6 (1.3) | 0 (0) |
| Biologic agent [ | 90 (19.7) | 124 (27.1) |
| JAK inhibitor [ | 14 (3.1) | 12 (2.6) |
| Other [ | 42 (9.2) | 53 (11.6) |
| Healthcare institutions where the treatment plan was selected at the time of UC relapse | ||
| National and public hospitals [ | 105 (23.0) | |
| University hospital [ | 132 (28.9) | |
| Clinic [ | 81 (17.7) | |
| Otherc [ | 139 (30.4) | |
| Time spent with the physician, min | When deciding on treatment | During routine clinical care |
| < 5 [ | 47 (10.3) | 112 (24.5) |
| 5 to < 10 [ | 147 (32.2) | 208 (45.5) |
| 10 to < 15 [ | 133 (29.1) | 96 (21.0) |
| 15 to < 30 [ | 73 (16.0) | 26 (5.7) |
| ≥ 30 [ | 57 (12.5) | 15 (3.3) |
| Patient decision-making preference scale (mean ± SD) | 2.6 ± 0.4 | |
ASA aminosalicylate, IV intravenous, JAK Janus kinase, PRO2 two-item patient-reported outcomes, UC ulcerative colitis
aSymptoms in the last 3 days
bPRO2 remission was defined as bleeding = 0 and stool frequency ≤ 1
cHospital other than a national and public hospital or university hospital
Fig. 1Physician–patient communication at the time of treatment decision-making. a Physician-to-patient information. b Patient-to-physician information
Fig. 2Patient satisfaction with treatment decision-making and patient trust in physicians. a DRS. b TIPS. aReversal items. DRS Decision Regret Scale, TIPS Trust in Physician Scale
Background characteristics correlating with DRS or TIPS
| Item | DRS | TIPS | ||||
|---|---|---|---|---|---|---|
| Correlation coefficienta | Correlation coefficienta | |||||
| Sex | − 0.037 | 0.424 | 0.424 | 0.048 | 0.305 | 0.305 |
| Age, years | 0.089 | 0.059 | – | − 0.016 | 0.735 | – |
| 20–34 years, 35–49 years, ≥ 50 years | – | – | 0.063 | – | – | 0.962 |
| Time since diagnosis, years | 0.104 | 0.026 | – | − 0.033 | 0.476 | – |
| ≤ 3 years, 4–9 years, ≥ 10 years | – | – | 0.225 | – | – | 0.306 |
| PRO2 score | 0.262 | < 0.001 | – | − 0.087 | 0.064 | – |
| PRO2 remission, non-remission | – | – | < 0.001 | – | – | 0.008 |
| Time spent with the physician when deciding on treatment | − 0.167 | < 0.001 | – | 0.252 | < 0.001 | – |
| < 10 min, 10 to < 15 min, ≥ 15 min | – | – | 0.001 | – | – | < 0.001 |
| Patient decision making preference scale | 0.215 | < 0.001 | – | − 0.215 | < 0.001 | – |
| ≤ 2.50c, ≥ 2.75 | – | – | < 0.001 | – | – | < 0.001 |
ANOVA analysis of variance, DRS Decision Regret Scale, PRO2 two-item patient-reported outcomes, TIPS Trust in Physician Scale, UC ulcerative colitis
aPearson’s correlation coefficient
bANOVA
cMedian
Fig. 3Path diagram in the structural equation modelling showing the relationship between physician–patient communication, patient satisfaction with treatment decision-making, and patient trust in physicians. The GFI, AGFI, and RMSEA of the path diagram, including patient-background correlated with DRS or TIPS with an absolute correlation coefficient of ≥ 0.2 were 0.908, 0.860, and 0.080, respectively. Values represent standardized path coefficients that indicate the degree of relationship between variables. *p < 0.05. aData reversing the five-level rank values of TIPS. AGFI adjusted goodness-of-fit index, DRS Decision Regret Scale, GFI Goodness-of-fit index, PRO2 two-item patient-reported outcomes, RMSEA root mean square error of approximation, TIPS Trust in Physician Scale
Fig. 4Correlation diagram between indirect effects of individual information items in the structural equation model and the proportions of patients who reported that information was “somewhat inadequate or inadequate” and information was “poorly communicated or never communicated”. Indirect effects were the value multiplied by the standardised path coefficient via the observed variables of information, the latent variables of information, and DRS or TIPS in the structural equation model. The lines show the mean value for each axis. aData reversing the five-level rank values of TIPS. DRS Decision Regret Scale, TIPS Trust in Physician Scale